Page 7 - Beta Bionics News Today

THURSDAY, Sept. 29, 2022 (HealthDay News) -- Reduction in glycated hemoglobin level is greater with use of a bionic pancreas compared with standard care in children and adults with type 1 diabetes, according to a study published in the Sept. 29 issue of the New England Journal of Medicine. Steven J. Russell, M.D., Ph.D., from

/PRNewswire/ -- Beta Bionics, Inc. — The results of the multi-center randomized Insulin-Only Bionic Pancreas Pivotal Trial (IO BPPT), which were presented in...

A device known as a bionic pancreas, which uses next-generation technology to automatically deliver insulin, was more effective at maintaining blood glucose (sugar) levels within normal range than standard-of-care management among people with type 1 diabetes, a new multicenter clinical trial has found.

The device controls blood sugar better than insulin shots while dramatically improving the patient's quality of life.

THURSDAY, Sept. 29, 2022 (HealthDay News) -- A new technology dubbed the "bionic pancreas" may beat standard treatment in helping people with type 1 diabetes control their blood sugar levels,

Investegate announcements from RTW Venture Fund Ltd, Half-year Report

Caution: The iLet® Bionic Pancreas and iLet Duo™ are investigational devices limited by Federal (or United States) law to investigational use. Not...

Beta Bionics announced today that a trial of its iLet bionic pancreas met key endpoints, including reduced HbA1c.

Zealand Pharma A/S (OTCMKTS:ZLDPF – Get Rating) and Amadeus IT Group (OTCMKTS:AMADY – Get Rating) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, dividends, earnings, institutional ownership and profitability. Risk and Volatility Zealand Pharma A/S has a […]

Results from the iLet Bionic Pancreas pivotal trial demonstrate that a system using a novel algorithm for automated insulin delivery may further ease patient burden.